AR060462A1 - Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 - Google Patents

Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3

Info

Publication number
AR060462A1
AR060462A1 ARP070101595A ARP070101595A AR060462A1 AR 060462 A1 AR060462 A1 AR 060462A1 AR P070101595 A ARP070101595 A AR P070101595A AR P070101595 A ARP070101595 A AR P070101595A AR 060462 A1 AR060462 A1 AR 060462A1
Authority
AR
Argentina
Prior art keywords
fluorinated
alkyl
alkoxy
cycloalkyl
alkenyl
Prior art date
Application number
ARP070101595A
Other languages
English (en)
Inventor
Roland Grandel
Wilfried Martin Braje
A Haupt
Sean Colm Turner
Udo Lange
Karla Drescher
Liliane Unger
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR060462A1 publication Critical patent/AR060462A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El uso de un compuesto de la formula (1) o una sal aceptable para uso farmacéutico del mismo para preparar una composicion farmacéutica para el tratamiento de un trastorno médico susceptible al tratamiento con un ligando del receptor do dopamina D3, SNC. Reivindicacion 1: Un compuesto ariloxietilamina de la formula (1) en donde Ar es fenilo o un radical heteroaromático unido por C de 5 o 6 miembros, en donde Ar puede llevar 1 radical Ra y en donde Ar también puede llevar 1 o 2 radicales Rb; Ra se selecciona entre el grupo formado por alquilo C1-6, alquilo fluorado C1-6, alquenilo C2-6, alquenilo fluorado C2-6, cicloalquilo C3-6, cicloalquilo fluorado C3-6, alcoxi C1-6, alcoxi fluorado C1-6, hidroxialquilo C1-6, alcoxi C1-6-alquilo C1-4, hidroxialcoxi C1-6, alcoxi- C1-6-alcoxi C1-4, COOH, NR4R5, CH2NR4R5, ONR4R5, NHC(O)NR4R5, C(O)NR4R5, SO2NR4R5, alquilcarbonilo C1-6, alquilcarbonilo fluorado C1-6, alquilcarbonilamino C1-6, alquilcarbonilamino fluorado C1-6, alquilcarboniloxi C1-6, alquilcarboniloxi fluorado C1-6, alcoxicarbonilo C1-6, alcoxicarbonilo fluorado C1-6, alquiltio C1-6, alquiltio fluorado C1-6, alquilsulfinilo C1-6, alquilsulfinilo fluorado C1-6, alquilsulfonilo C1-6, alquilsulfonilo fluorado C1-6, fenilsulfonilo, fenilo, fenoxi, benciloxi, piridin-2-iloxi y un radical heterocíclico de entre 3 y 7 miembros, en donde los grupos fenilo, el grupo piridilo y el grupo heterociclilo en los ultimos seis radicales mencionados pueden llevar 1 2, 3 o 4 radicales seleccionados entre halogeno, ciano, OH, oxo, CN, y un radical Raa, en donde Raa se selecciona entre alquilo C1-6, alquilo fluorado C1-6, alquenilo C2-6, alquenilo fluorado C2-6, cicloalquilo C3-6, cicloalquilo fluorado C3-6, alcoxi C1-6, alcoxi fluorado C1-6, hidroxialquilo C1-6 ,alcoxi C1-6-alquilo C1-4, hidroxialcoxi C1-6, alcoxi C1-6-alcoxi C1-4, COOH, NR4R5, CH2NR4R5, ONR4R5, NHC(O)NR4R5, C(O)NR4R5, SO2NR4R5, alquilcarbonilo C1-6, alquilcarbonilo fluorado C1-6, alquilcarbonilamino C1- 6, alquilcarbonilamino fluorado C1-6, alquilcarboniloxi C1-6, alquilcarboniloxi fluorado C1-6, alcoxicarbonilo C1-6, alcoxicarbonilo fluorado C1-6, alquiltio C1-6, alquiltio fluorado C1-6, alquilsulfinilo C1-6, alquilsulfinilo fluorado C1-6, alquilsulfonilo C1-6, alquilsulfonilo fluorado C1-6; cada Rb se selecciona entre halogeno, ciano, nitro, OH, metilo, metoxi, fluorometilo, difluorometilo, trifluorometilo, fluormetoxi, difluorometoxi y trifluorometoxi, o el radical Ra y un radical Rb, de estar presentes, unidos a dos átomos de carbono adyacentes de fenilo, pueden formar un anillo heterocíclico o carbocíclico de 5 o 6 miembros que está unido al anillo fenilo y que no está sustituido o que puede llevar 1, 2 o 3 radicales seleccionados entre halogeno, NO2, NH2, OH, CN, alquilo C1-6, alquilo fluorado C1-6, cicloalquilo C3-6, cicloalquilo fluorado C3-6, alcoxi C1-6, alcoxi fluorado C1-6, hidroxialquilo C1-6, alcoxi-C1-4-alquilo C2-4, hidroxialcoxi C1-6, alcoxi-C1-4- alcoxi C2-4, alquilcarbonilo C1-6, alquilcarbonilo fluorado C1-6, alquilamino C1-6, di-C1-6-alquilamino, alquilaminocarbonilo C1-6, di-C1-6 alquilaminocarbonilo, alquilcarbonilamino C1-6, alquilcarbonilamino fluorado C1-6, alquilcarboniloxi C1-6, alquilcarboniloxi fluorado C1-6, alcoxicarbonilo C1-6, alquiltio C1-6, alquiltio fluorado C1-6, alquilsulfinilo C1-6, alquilsulfinilo fluorado C1-6, alquilsulfonilo C1-6, y alquilsulfonilo fluorado C1-6, X es N o CH; R1 es H, alquilo C1-4, cicloalquilo C3-4, cicloalquilmetilo C3-4, alquenilo C3-4, alquilo fluorado C1-4, cicloalquilo fluorado C3-4, cicloalquilmetilo fluorado C3-4, alquenilo fluorado C3-4, formilo o alquilcarbonilo C1-3; R1a es H, alquilo C1-4, cicloalquilo C3-4, cicloalquilmetilo C3-4, alquenilo C3-4, alquilo fluorado C1-4, cicloalquilo fluorado C3-4, cicloalquilmetilo fluorado C3-4, o alquenilo fluorado C3-4, o R1 y R1a juntos son (CR6R7)r donde r es 3, 4 o 5; R2 y R2a son en forma independiente entre sí H, F, alquilo C1-4 o alquilo fluorado C1-4 o R2a y R2 juntos pueden formar un miembro del anillo (CR6R7)m donde m es 2, 3, 4 o 5; oR1a y R2a juntos son (CR6R7)n donde n es 2, 3 o 4; R3 es H o alquilo C1-4; R4, R5 en forma independiente entre sí y en forma independiente de cada aparicion se seleccionan entre H, alquilo C1-3, alcoxi C1-3 y alquilo fluorado C1-3; R6, R7 en forma independiente entre sí y en forma independiente de cada aparicion se seleccionan entre H, F, alquilo C1-4 y alquilo fluorado C1-4; R8, R8a en forma independiente entre sí son H, F, alquilo C1-4 o alquilo fluorado C1-4 o R8a y R8 juntos pueden formar un miembro del anillo (CR6R7)q donde q es 2, 3, 4 o 5, R1a y R8a juntos son (CR6R7)n donde n es 2 o 3; y R9 es H, alquilo C1-4, alquilo fluorado C1-4, alcoxi C1-4, o alcoxi fluorado C1-4; y las sales de adicion ácida fisiologicamente tolerables del mismo.
ARP070101595A 2006-04-14 2007-04-13 Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 AR060462A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06007923 2006-04-14
US79367106P 2006-04-20 2006-04-20

Publications (1)

Publication Number Publication Date
AR060462A1 true AR060462A1 (es) 2008-06-18

Family

ID=38180343

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101595A AR060462A1 (es) 2006-04-14 2007-04-13 Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3

Country Status (8)

Country Link
US (1) US8383641B2 (es)
EP (1) EP2013179B1 (es)
JP (1) JP5232987B2 (es)
AR (1) AR060462A1 (es)
CA (1) CA2648543C (es)
MX (1) MX2008013114A (es)
UY (1) UY30284A1 (es)
WO (1) WO2007118859A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20142099A1 (es) 2009-01-12 2014-12-13 Icagen Inc Derivados de sulfonamida
AU2010231694A1 (en) 2009-03-30 2011-10-06 Astellas Pharma Inc. Pyrimidine compound
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
WO2013074965A1 (en) * 2011-11-16 2013-05-23 Microbiotix, Inc. Aminoalkyl phenol ether inhibitors of influenza a virus
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2018164192A1 (ja) * 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
CN118271298A (zh) 2019-01-31 2024-07-02 武田药品工业株式会社 杂环化合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW450954B (en) 1998-05-14 2001-08-21 Pharmacia & Amp Upjohn Company Phenylsulfonamide-phenylethylamines useful as dopamine receptors
EP1809597B1 (en) * 2004-10-14 2012-01-11 Abbott GmbH & Co. KG Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor

Also Published As

Publication number Publication date
JP2009533397A (ja) 2009-09-17
US8383641B2 (en) 2013-02-26
EP2013179A1 (en) 2009-01-14
US20090143383A1 (en) 2009-06-04
CA2648543C (en) 2015-06-02
UY30284A1 (es) 2007-11-30
MX2008013114A (es) 2008-10-21
JP5232987B2 (ja) 2013-07-10
WO2007118859A1 (en) 2007-10-25
CA2648543A1 (en) 2007-10-25
EP2013179B1 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
AR060462A1 (es) Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3
AR078786A1 (es) Derivados de la cromenona
AR072839A1 (es) Derivados adamantil diamida y usos de los mismos
AR127309A2 (es) Derivados de piridazinona
AR051342A1 (es) Derivados de purina, purinona, deazapurina y deazapurinona como inhibidores de la actividad de la protein quinasa; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la protein quina
AR057062A1 (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
CA2444634A1 (en) Spiropyrazole compounds
AR068846A1 (es) Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
PH12020550921A1 (en) Cap-dependent endonuclease inhibitors
PE20211703A1 (es) Compuesto derivado heterotriciclico novedoso y uso del mismo
AR105122A1 (es) INHIBIDORES DE METALO-b-LACTAMASA
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
AR085354A1 (es) Derivados de isoxazol para control de pestes invertebrados
AR056892A1 (es) Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AR054799A1 (es) Derivados de oxindol
AR077130A1 (es) Inhibidores de la replicacion de los virus de influenza
AR055321A1 (es) Compuestos de imidazopiridina uso para a fabricacion de un medicamento para el tratamiento o profilaxis de enfermedades o trastornos en los que se requiere un antagonista de una bomba de acido y composicion farmaceutica que lo comprende
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
AR051325A1 (es) Analogos de biarilquinolin-4-ilamina sustituidos
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
AR045389A1 (es) Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido
AR049577A1 (es) Derivados de hidantoina, procesos para su preparacion, composiciones y su uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal